Alzheimer’s disease (AD) is a devastating and progressive disease without a cure. Neuroinflammation is now recognized as a key early event in the development of AD. A non-invasive imaging method to detect and assess early damaging neuroinflammation would be able to detect disease before irreversible damage occurs. We at Einsenca are developing a PET imaging method to detect and monitor oxidative stress and consequent damaging neuroinflammation in AD. Intellectual property protections will be critical to future commercialization and ultimate clinical translation of these PET imaging methods. We request administrative supplement support for technical assistance with these intellectual property protections. Currently Einsenca possesses limited rights for development and validation of these PET imaging technologies that originated at academic partner Massachusetts General Hospital (MGH). TABA support will be used to fund ahighly experienced attorney from a full-service national law firm (Potomac Law Group) to evaluate the strength, validity, and enforceable nature of the patents intended to be exclusively licensed by Einsenca along with anticipated freedom to operate and commercialize the technology. Potomac Law Group will also assist Einsenca in the financial valuation of the technology and draft, negotiate and conclude the definitive exclusive license agreement between Einsenca and MGH. Finally, Potomac Law Group will draft templates and assist in negotiation of sponsored research, materials transfer, and confidentiality agreements important for development work with both commercial and academic partners.